Yondelis

Active Ingredient(s): Trabectedin
FDA Approved: * October 23, 2015
Pharm Company: * JANSSEN PRODS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Yondelis Overview

Trabectedin (also known as ecteinascidin 743 or ET-743) is an antitumor chemotherapy drug sold by Pharma Mar S.A. and Johnson and Johnson under the brand name Yondelis. It is approved for use in Europe, Russia, and South Korea for the treatment of advanced soft-tissue sarcoma. It is also undergoing clinical trials for the treatment of breast, prostate, and paediatric sarcomas. The European Commission and the U.S. Food and Drug Administration (FDA) have granted orphan drug status to trabecte...

Read more Yondelis Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Trabectedin

Recent Yondelis Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Yondelis: (1 result)

Sorted by National Drug Code

• 59676-610 Yondelis .05 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution by Janssen Products, Lp

Other drugs which contain Trabectedin or a similar ingredient: (1 result)

• TRABECTEDIN